News
Market Mover
Germany's Merck Acquires Bio-Techne for $11.3 Billion to Expand Life Sciences
Suhaib
Executive summary
German pharmaceutical giant Merck KGaA announced an $11.3 billion acquisition of Minnesota-based Bio-Techne, its largest deal in over a decade. The purchase strengthens Merck's foothold in life sciences tools used for drug discovery and gene therapy, while Bio-Techne shareholders see immediate gains after years of underperformance.
What happened
Merck KGaA agreed to acquire Bio-Techne for $73 per share, valuing the deal at $11.3 billion. Bio-Techne manufactures lab materials and equipment critical to drug development, including recombinant proteins, antibodies, and immunoassay kits. The Minneapolis-based company has over 3,000 employees and generated $1.2 billion in revenue last year. The acquisition follows pressure from activist investor Ananym Capital Management, which urged Bio-Techne's board to explore a sale after the stock fell nearly 50% over five years. Merck expects the transaction to deliver approximately $159 million in cost savings over three years and will expand the German drugmaker's presence in the US market.
Why the stock moved
Bio-Techne shares surged nearly 20% following the announcement, as the $73 per share offer represented a significant premium to recent trading levels. Merck KGaA stock rose about 5% as investors welcomed the strategic expansion into high-margin consumables and lab tools. The deal comes as biotech companies struggle with reduced research funding, making Bio-Techne an attractive target. Over 80% of Bio-Techne's sales come from consumables that require frequent replacement, providing steady recurring revenue that appeals to acquirers in a consolidating sector.
Bigger picture
The acquisition reflects broader consolidation in life sciences as larger pharmaceutical companies acquire struggling biotech firms. Bio-Techne thrived during the COVID-19 pandemic when research funding surged, but shares peaked in 2021 and declined as capital dried up. Merck's new CEO Kai Beckmann has emphasized growth through acquisitions, previously purchasing SpringWorks Therapeutics for $3.9 billion earlier this year. Rival giants Thermo Fisher Scientific and Danaher have also spent billions acquiring life sciences specialists in recent months. The deal marks one of Minnesota's largest corporate acquisitions, though it means the state will lose another headquarters.
What investors watch
Regulatory and shareholder approvals remain pending for the transaction. Investors will monitor whether the deal triggers further consolidation in the biotech sector, as Beckmann predicted more mergers ahead. Key questions include potential job cuts or facility relocations, which Bio-Techne has not addressed publicly. Merck's ability to integrate Bio-Techne's portfolio of over 3,000 products and achieve projected cost savings will be critical. Broader trends in biotech research funding and demand for lab consumables will also influence the combined company's performance.
